← Back to Search

Chemotherapy

Arm I: R-mabHD for Hodgkin's Lymphoma

Phase 2
Waitlist Available
Led By Prem A Nandiwada, M.D.
Research Sponsored by American Scitech International
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up six months
Awards & highlights

Study Summary

120 subjects with Hodgkin's disease will be randomly divided into two groups: Group I receiving R-mabHD and Group II receiving a combination of Adriamycin,Bleomycin,Vinblastine and Dacarbazine. R-mabHD will be given once a week for eight weeks in a row. The ABVD combination will be given once every other week for 12 treatments. The hypothesis is that intervention with R-mabHD will lead to a quicker remission of Hodgkin's disease than the intervention with a combination of ABVD.

Eligible Conditions
  • Hodgkin's Lymphoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~eighteen months
This trial's timeline: 3 weeks for screening, Varies for treatment, and eighteen months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
There will be a reduction in the size of the tumor after initiating treatment.
Secondary outcome measures
There will be an improvement in the general condition of the patient and it will be possible to estimate the event free survival rate.

Trial Design

2Treatment groups
Active Control
Group I: Arm I: R-mabHDActive Control1 Intervention
Anti-hodgkin disease agent
Group II: Arm II: ABVDActive Control1 Intervention

Find a Location

Who is running the clinical trial?

Bristol-Myers SquibbIndustry Sponsor
2,642 Previous Clinical Trials
4,130,003 Total Patients Enrolled
American Scitech InternationalLead Sponsor
5 Previous Clinical Trials
2,690 Total Patients Enrolled
Eli Lilly and CompanyIndustry Sponsor
2,621 Previous Clinical Trials
3,216,502 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Study Comparing R-mabHD and a Combination of ABVD in Hodgkin's Disease
2011. "Study Comparing R-mabHD and a Combination of ABVD in Hodgkin's Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00797472.
All > Hodgkins Lymphoma
~9 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top